Medication use for the treatment of diabetes in obese individuals

Diabetologia

Volumn 61, Issue 2, 2018, Pages 265-272

  Wilding, John P H ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Diabetes; GLP 1 agonists; Lorcaserin; Naltrexone bupropion; Obesity; Orlistat; Phentermine topiramate; Review; SGLT2

Indexed keywords

AMINOPEPTIDASE INHIBITOR; ANTIDIABETIC AGENT; CANAGLIFLOZIN; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN RECEPTOR AGONIST; METHIONYL AMINOPEPTIDASE 2; PEPTIDE DERIVATIVE; PHENTERMINE; AMFEBUTAMONE; BENZAZEPINE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; LACTONE; LORCASERIN; NALTREXONE; TETRAHYDROLIPSTATIN;

BODY WEIGHT; DIABETES MELLITUS; DIABETIC PATIENT; DRUG USE; EXPERIMENTAL MEDICINE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; WEIGHT CHANGE; WEIGHT REDUCTION; AGONISTS; ANIMAL; METABOLISM;

ANIMALS; BENZAZEPINES; BUPROPION; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LACTONES; NALTREXONE; OBESITY;

EID: 85019251861     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4288-1     Document Type: Review

References (45)

1. Skyler JS, Bakris GL, Bonifacio E et al (2017) Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes 66:241–255
2. Raum P, Lamparter J, Ponto KA et al (2015) Prevalence and cardiovascular associations of diabetic retinopathy and maculopathy: results from the Gutenberg Health Study. PLoS One 10:e0127188
3. Carnethon MR (2012) Association of weight status with mortality in adults with incident diabetes. JAMA 308:2085–2085
4. Henry RR, Brechtel G, Griver K (1988) Secretion and hepatic extraction of insulin after weight-loss in obese noninsulin-dependent diabetes-mellitus. J Clin Endocrinol Metab 66:979–986
5. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R (2011) Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 54:2506–2514
6. Mingrone G, Panunzi S, De Gaetano A et al (2015) Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 386:964–973
7. Cefalu WT, Bray GA, Home PD et al (2015) Advances in the science, treatment, and prevention of the disease of obesity: reflections from a diabetes care editors’ expert forum. Diabetes Care 38:1567–1582
8. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
9. Bray GA, Fruhbeck G, Ryan DH, Wilding JPH (2016) Management of obesity. Lancet 387:1947–1956
10. Wing R, Bolin P, Brancati FL et al (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369:145–154
11. Zhang P, Hire D, Espeland MA et al (2016) Impact of intensive lifestyle intervention on preference-based quality of life in type 2 diabetes: results from the Look AHEAD trial. Obesity 24:856–864
12. Wing RR, Espeland MA, Clark JM et al (2016) Association of weight loss maintenance and weight regain on 4-year changes in CVD risk factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial. Diabetes Care 39:2318–2318
13. Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58:429–442
14. Palmer SC, Mavridis D, Nicolucci A et al (2016) Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 316:313–324
15. Makimattila S, Nikkila K, Yki-Jarvinen H (1999) Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 42:406–412
16. Russell-Jones D, Khan R (2007) Insulin-associated weight gain in diabetes—causes, effects and coping strategies. Diabetes Obes Metab 9:799–812
17. Hirose H, Kawai T, Yamamoto Y et al (2002) Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51:314–317
18. Wilding J (2006) Thiazolidinediones, insulin resistance and obesity: finding a balance. Int J Clin Pract 60:1272–1280
19. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E (2015) Energy balance after sodium glucose cotransporter 2 (SGLT2) inhibition. Diabetes Care 38:1730–1735
20. Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Knudsen LB (2012) Liraglutide: short-lived effect on gastric emptyingulong lasting effects on body weight. Diabetes Obes Metab 14:531–538
21. Turton MD, O'Shea D, Gunn I et al (1996) A role for glucagon-like peptide-1 in the central control of feeding. Nature 379:69–72
22. Pratley RE, Nauck MA, Barnett AH et al (2014) Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2:289–297
23. Zachariah S, Sheldon B, Shojaee-Moradie F et al (2011) Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes. Diabetes Care 34:1487–1491
24. Frias JP, Guja C, Hardy E et al (2016) Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 4:1004–1016
25. Wilding JPH, Bain SC (2016) Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in type 2 diabetes, with special reference to IDegLira. Diabet Med 33:864–876
26. Cuthbertson DJ, Irwin A, Gardner CJ et al (2012) Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One 7:e50117
27. Cefalu WT, Stenlof K, Leiter LA et al (2015) Effects of canagliflozin on body weight and relationship to HbA(1c) and blood pressure changes in patients with type 2 diabetes. Diabetologia 58:1183–1187
28. Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:2247–2257
29. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
30. Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322
31. Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844
32. Liu W, Yang XJ (2016) The effect of metformin on adolescents with type 1 diabetes: a systematic review and meta-analysis of randomized controlled trials. Int J Endocrinol 2016:3854071
33. Dejgaard TF, Frandsen CS, Hansen TS et al (2016) Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 4:221–232
34. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB (2015) Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38:1687–1693
35. Ruof J, Golay A, Berne C, Collin C, Lentz J, Maetzel A (2005) Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland. Int J Obes 29:517–523
36. Davies MJ, Bergenstal R, Bode B et al (2015) Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314:687–699
37. O'Neil PM, Smith SR, Weissman NJ et al (2012) Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity 20:1426–1436
38. Hollander P, Gupta AK, Plodkowski R et al (2013) Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 36:4022–4029
39. Garvey WT, Ryan DH, Bohannon NJV et al (2014) Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care 37:3309–3316
40. Janssen Research & Development (2016) Effects of co-administration of canagliflozin 300 mg and phentermine 15 mg with placebo in the treatment of non-diabetic overweight and obese participants. Available from https://clinicaltrials.gov/ct2/show/results/NCT02243202. Accessed 29 December 2016
41. Kuhnen P, Clement K, Wiegand S et al (2016) Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med 375:240–246
42. Kim DD, Krishnarajah J, Lillioja S et al (2015) Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. Diabetes Obes Metab 17:566–572
43. Rodgers RJ, Tschöp MH, Wilding JPH (2012) Anti-obesity drugs: past, present and future. Dis Models Mech 5:621–626
44. Finan B, Yang B, Ottaway N et al (2015) A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21:27–36
45. Tschöp MH, Finan B, Clemmensen C et al (2016) Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab 24:51–62